215 patents
Page 9 of 11
Utility
Composition for Inhalation
11 Mar 21
The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases.
Nayna Govind, Maria Marlow
Filed: 27 Mar 20
Utility
Compositions and Methods for Treating Late Stage Lung Cancer
11 Mar 21
Disclosed are methods for treating extensive-stage small-cell lung cancer (ES-SCLC) with an antibody that inhibits PD1/PD-L1 activity in combination with etoposide and a platinum-based therapeutic agent.
HAIYI JIANG, YIFAN HUANG, PHILLIP DENNIS, NORAH SHIRE, JON ARMSTRONG
Filed: 4 Sep 20
Utility
Methods of Treating Heart Failure with Reduced Ejection Fraction
4 Mar 21
The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Anna Maria LANGKILDE
Filed: 9 Mar 20
Utility
Therapeutic Dendrimers
4 Mar 21
Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
Filed: 11 Nov 20
Utility
Inhibitors of Phosphatidylinositol 3-KINASE Gamma
18 Feb 21
Mickael MOGEMARK, Nils PEMBERTON, Jens PETERSEN, Matthew PERRY, Konstantinos KARABELAS, Pavol ZLATOIDSKY, Rhona COX, Christian TYRCHAN
Filed: 4 Nov 20
Utility
Nmda Antagonist Prodrugs
11 Feb 21
Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
Filed: 26 Oct 20
Utility
Chemical Compounds
11 Feb 21
Jeffrey Wallace JOHANNES, Sudhir Mahadeo HANDE, Sebastien Louis DEGORCE, Martin John PACKER
Filed: 17 Jul 20
Utility
Combinations for Treating Cancer
4 Feb 21
Disclosed are methods of treating cancer comprising administering 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6, 12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1 (37), 4(38), 6, 11, 14, 16, 18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, a pharmaceutically acceptable salt thereof; and acalabrutinib, or a pharmaceutically acceptable salt thereof.
Scott BOIKO, Justin CIDADO, Lisa DREW, Theresa PROIA, Maryann SAN MARTIN
Filed: 29 Apr 19
Utility
Computer System and Method for Generating Trigger Alerts to Maximize Interactions With Healthcare Providers
21 Jan 21
A pharmaceutical company may employ a computer system that is configured to analyze anonymized patient data for patients treated by each of a plurality of healthcare providers (HCPs) to determine whether each such HCP is likely to make a given type of treatment decision for at least one patient in the foreseeable future.
Kishore Kumar
Filed: 7 Oct 20
Utility
Inhaler
14 Jan 21
An inhaler for delivery of a medicament by inhalation is disclosed.
BILL TRENEMAN, CHARLOTTE LEEDER, ANDREW HALKET, SIMON INGRAM, CHRIS HURLSTONE, VALERIO LELIO CEREDA, JOE DAINTREY, WARREN ISAACS, MARTIN KARLSSON, JAKE CHRISTOFFERSON, RUNE DUCCE, SIMON BERRY
Filed: 6 Mar 19
Utility
Arginase Inhibitors and Methods of Use Thereof
6 Jan 21
Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON, Jianyan WANG, Steve COOK, Dedong WU
Filed: 14 Feb 19
Utility
Use of Myeloperoxidase (Mpo) Inhibitors or Pharmaceutically Acceptable Salts Thereof to Treat Multiple System Atrophy (Msa) 938
30 Dec 20
The present invention relates to the use of MPO inhibitors for the treatment of multiple system atrophy.
Hakan Eriksson, Werner Poewe
Filed: 12 Sep 20
Utility
Medicament Dispensing System and Dispensing Method
9 Dec 20
A dispensing system (2) and method for dispensing unit dosage forms (38) from a blister pack (30) is disclosed.
FREDRIK JONSSON, LUBOMIR GRADINARSKY
Filed: 4 Jul 18
Utility
Osimertinib for Use In the Treatment of Non-small Cell Lung Cancer
25 Nov 20
The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.
Anthony Francis Patrick NASH
Filed: 10 Feb 19
Utility
Cell Lines and Methods for Increased Protein Production
25 Nov 20
The present technology relates generally to methods for increasing recombinant protein production in various cells lines.
ROBERT ROTH, LORENZ MAYR
Filed: 1 Oct 18
Utility
Pharmaceutical Compositions Comprising AZD9291
18 Nov 20
The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
Cindy FINNIE, Steven Anthony RAW, David WILSON
Filed: 3 Aug 20
Utility
Methods for Treating Chronic Obstructive Pulmonary Disease In an Enhanced Patient Population Using Benralizumab
18 Nov 20
Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
Paul NEWBOLD, Ubaldo MARTIN, Maria JISON, Peter BARKER
Filed: 14 May 20
Utility
5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -One Derivatives and Their Use As Dual Inhibitors of Phosphatidylinositol 3-KINASE Delta & Gamma
30 Sep 20
Matthew PERRY, Christian TYRCHAN, Konstantinos KARABELAS, Antonios NIKITIDIS, Mickael MOGEMARK, Jens PETERSEN, Peter BOLD, Ulf BORJESSON
Filed: 20 Sep 17
Utility
Stable, Aqueous Formulations of Antibodies That Bind IL5 Receptor
23 Sep 20
The present invention relates to stable, aqueous antibody formulations.
William LEACH, Rachael LEWUS, James MCGIVNEY, Kelcy NEWELL, Kevin Douglas STEWART
Filed: 24 Mar 20
Utility
Novel Inhibitors of Phosphatidylinositol 3-KINASE Gamma
23 Sep 20
Mickael MOGEMARK, Nils PEMBERTON, Jens PETERSEN, Matthew PERRY, Konstantinos KARABELAS, Pavol ZLATOIDSKY, Rhona COX, Christian TYRCHAN
Filed: 8 Mar 17